{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:50:48Z","timestamp":1792407048665,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.diabres.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T12:47:59Z","timestamp":1407847679000},"page":"264-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials"],"prefix":"10.1016","volume":"106","author":[{"given":"David R.","family":"Owens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Dain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2014.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2014.08.003_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2003-39080","article-title":"A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes","volume":"35","author":"Massi Benedetti","year":"2003","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabres.2014.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2014.08.003_bib0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2014.08.003_bib0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1463-1326.2011.01412.x","article-title":"An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia","volume":"13","author":"Fonseca","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2014.08.003_bib0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2014.08.003_bib0035","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2014.08.003_bib0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2014.08.003_bib0045","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-010-1864-z","article-title":"Intensified glucose lowering in type 2 diabetes: time for a reappraisal","volume":"53","author":"Yudkin","year":"2010","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2014.08.003_bib0050","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1089\/dia.2011.0068","article-title":"Insulin preparations with prolonged effect","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2014.08.003_bib0055","first-page":"38","article-title":"Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs","volume":"9","author":"Brunton","year":"2007","journal-title":"MedGenMed"},{"key":"10.1016\/j.diabres.2014.08.003_bib0060","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1210\/jc.2007-2871","article-title":"Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes","volume":"93","author":"Linn","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2014.08.003_bib0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diaclin.25.1.36","article-title":"Overcoming barriers to the initiation of insulin therapy","volume":"25","author":"Funnell","year":"2007","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.diabres.2014.08.003_bib0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00592-008-0052-9","article-title":"The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes","volume":"45","author":"Baxter","year":"2008","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2014.08.003_bib0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0973-3930.43102","article-title":"Starting insulin in type 2 diabetes: overcoming barriers to insulin therapy","volume":"28","author":"Kabadi","year":"2008","journal-title":"Int J Diabetes Dev Ctries"},{"key":"10.1016\/j.diabres.2014.08.003_bib0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1098-3597(09)62041-X","article-title":"Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus","volume":"9","author":"Marrero","year":"2008","journal-title":"Clin Cornerstone"},{"key":"10.1016\/j.diabres.2014.08.003_bib0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17925\/EE.2014.10.01.23","article-title":"A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes","volume":"10","author":"DeVries","year":"2014","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.diabres.2014.08.003_bib0090","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial","volume":"379","author":"Aschner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2014.08.003_bib0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4158\/EP09281.OR","article-title":"Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"16","author":"Meneghini","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2014.08.003_bib0100","unstructured":"ClinicalTrials.gov identifier: NCT00046462. Determine whether glycemic control is different between Lantus & and 3rd oral agent when failure with other treatment."},{"key":"10.1016\/j.diabres.2014.08.003_bib0105","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"Gerstein","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2014.08.003_bib0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2014.08.003_bib0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/diacare.28.2.419","article-title":"Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride","volume":"28","author":"Standl","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1016\/j.diabres.2014.08.003_bib0130","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-na\u00efve patients","volume":"29","author":"Rosenstock","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0140","unstructured":"ClinicalTrials.gov identifier: NCT01336751. Lantus versus Humalog mix as add-on therapy in type diabetes patients failing sulfonylurea and metformin combination treatment."},{"key":"10.1016\/j.diabres.2014.08.003_bib0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0150","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","article-title":"Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups","volume":"30","author":"Yki-J\u00e4rvinen","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1463-1326.2008.00980.x","article-title":"Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7\u20138% A1c levels. The TULIP study","volume":"11","author":"Blickl\u00e9","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2014.08.003_bib0160","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/db09-1774","article-title":"Associations between features of glucose exposure and A1C: the A1C-Derived Average Glucose (ADAG) study","volume":"59","author":"Borg","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2014.08.003_bib0165","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.2337\/dc13-2088","article-title":"Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes","volume":"36","author":"Porcellati","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0170","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.08.003_bib0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1464-5491.2009.02899.x","article-title":"A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes","volume":"27","author":"Fogelfeld","year":"2010","journal-title":"Diabet Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T17:10:26Z","timestamp":1565716226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822714003271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168822714003271"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2014.08.003","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}